Home » Stocks » Galapagos

Galapagos NV (GLPG)

Stock Price: $190.03 USD -3.81 (-1.96%)
Updated Aug 4, 2020 3:14 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 12.40B
Revenue (ttm) 1.01B
Net Income (ttm) 168.37M
Shares Out 65.25M
EPS (ttm) -1.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $190.03
Previous Close $193.83
Change ($) -3.81
Change (%) -1.96%
Day's Open 190.23
Day's Range 188.41 - 190.66
Day's Volume 61,828
52-Week Range 112.00 - 274.03

More Stats

Market Cap 12.40B
Enterprise Value 5.93B
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 65.25M
Float 41.57M
EPS (basic) n/a
EPS (diluted) -1.69
FCF / Share 65.25
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 28.66%
Payout Ratio n/a
Shares Short 1.04M
Short Ratio 9.97
Short % of Float n/a
Beta 1.08
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 3.49
PS Ratio 12.32
PB Ratio 3.65
Revenue 1.01B
Operating Income 416.06M
Net Income 168.37M
Free Cash Flow 3.55B
Net Cash 6.47B
Net Cash / Share 99.10
Gross Margin 100.00%
Operating Margin 41.33%
Profit Margin 16.70%
FCF Margin 353.05%
ROA 6.41%
ROE 7.37%
ROIC 8.40%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (18)

Buy 6
Overweight 0
Hold 11
Underweight 1
Sell 0

Analyst Consensus: Overweight

Price Target

$221.63*
(16.63% upside)
Low
150
Current: $190.03
High
313
Target: 221.63
*Average 12-month USD price target from 16 stock analysts.

Financial Performance

Financial numbers in millions EUR.

Financial Overview

Year20192018201720162015201420132012
Revenue89631815615260.5890.0296.5792.23
Revenue Growth181.86%103.85%2.84%150.27%-32.71%-6.78%4.71%-
Gross Profit89631815615260.5890.0296.5786.64
Operating Income370-44.81-89.80-11.49-89.44-36.63-16.92-9.53
Net Income150-29.26-11654.01-11833.21-8.08-5.72
Shares Outstanding54.4752.1149.4845.7035.7030.1128.7926.55
Earnings Per Share2.49-0.56-2.341.14-3.321.10-0.28-0.22
Operating Cash Flow3,209-142-147239-115-75.561.8565.87
Capital Expenditures-45.69-13.72-7.43-4.77-6.56-2.76-7.81-6.44
Free Cash Flow3,163-156-154235-121-78.31-5.9659.44
Cash & Equivalents5,7811,2911,15197334719813894.37
Total Debt25.38-0.010.060.120.170.390.41
Net Cash / Debt5,7551,2911,15197334719813893.96
Assets6,0691,4391,2861,083443270287235
Liabilities3,19322527432577.5264.33120117
Book Value2,8761,2141,012759365206167118
Numbers in millions EUR, except per-share numbers.

Company Profile

Company Details

Full Name Galapagos NV
Country Belgium
Employees 1,130
CEO Onno van de Stolpe

Stock Information

Ticker Symbol GLPG
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GLPG
IPO Date May 6, 2005

Description

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.